Authors
Latest:
Optimizing Clinical Trials Using Electronic Measurement and Analysis of Drug AdherenceDrug development has never before been so difficult, time consuming and expensive. Accuracy in clinical trials, therefore, is a priority
Latest:
Sales Personnel Contracts, Sword or Shield for M&A ValuationDetermining a company’s acquisition/merger value requires an intensive due diligence process. Attorney Gregg Metzger discusses salesforce contracts which, especially for life science companies, cannot be overlooked.
Latest:
Towards Real-World Patient CentricityPatient centricity requires clinical trials to be based on life outside the lab, writes Mads Holme.
Latest:
Why Is It Such a Challenge to Treat PAH?Despite recent advances, there continue to be significant issues that compromise the effective management of pulmonary arterial hypertension, writes Victoria Allan.
Latest:
Divergent Paths: Pharm Exec Profiles Five Recent Drug LaunchesPharm Exec’s latest sampling of notable biopharma brand approvals and launches all have unique stories to tell—from the winding journeys to innovative “firsts” to new momentum for milestones to come.
Latest:
The Salix-Valeant Acquisition: "It’s Just a Game"Sarah Chaney gives an in-depth look at the Salix-Valeant acquisition - how analysts and investors can affect decision-making and potentially drive poor behavior.
Latest:
Patient-centric innovation in packaging moves beyond regulatory requirements to deliver brand differentiation and increased salesNot so long ago, pharmaceutical brand managers considered drug packaging an afterthought. Today, packaging not only matters, it is quickly becoming one of the most important considerations in the growth and success of any drug product. Manufacturers now consider innovative, smart packaging that pleases patients in their new roles as consumers, and encourages brand loyalty to be a game changer in an increasingly competitive and crowded biopharmaceutical market.
Latest:
Europe Needs News Timeline for IDMP ImplementationAll indications are that the July 2016 deadline for transition from Europe's eXtended EudraVigilance Medicinal Product Dictionary (XEVMPD) to the new Identification of Medicinal Products (IDMP) is not achievable. Sophie Daniels reports.
Latest:
Resell vs. Direct Models: US Branded Drug Distribution in the FutureKathleen Iacocca and Yao Zhao discuss why direct supply chain models can be more sustainable than resell models in the long run and whether they can be implemented in the US.
Latest:
New Payment Models: It's Time to MoveCommercial success for pharma brands now demands proactive strategies and interventions
Latest:
New Payment Models: It's Time to MoveCommercial success for pharma brands now demands proactive strategies and interventions
Latest:
Why Patient-Centric Innovation Holds the Key to Long-Term Business Success for Companies in China’s Booming Biotech SectorAssessing the road ahead for Chinese biotech.
Latest:
Stop Everything! Investigating FCPA Issues in PharmaAn internal audit of payment practices in Eastern Europe has revealed payments for elaborate travel for government health authorities and state-employed physicians in exchange for approval and prescription of your products. What is the first thing you should do? Lawyer Mara Senn offers some advice.
Latest:
How eTMFs Are Transforming the Pharma IndustryA significant change is under way as the industry shifts from passive to active trial master file (TMF) management, writes Rik van Mol.
Latest:
Walgreens: Purveyor or Provider?The merger announcement from Walgreens Boots Alliance and Rite Aid throws up an interesting question, writes Stephen Littlejohn. Will Walgreens be purveyor focused on retail sales or provider engaged with a transforming U.S. healthcare system?
Latest:
Biosimilar Litigation: Lessons So FarThe case of Amgen v. Sandoz signals that preliminary injunctions will play major role in future patent disputes
Latest:
Biosimilar Litigation: Lessons So FarThe case of Amgen v. Sandoz signals that preliminary injunctions will play major role in future patent disputes
Latest:
Restricted Access Essentials for PharmaWhere is US payer formulary management heading-and what can the industry do to help influence its course?
Latest:
Open Payments: Key Compliance ConsiderationsOn June 30, the Centers for Medicare and Medicaid Services (CMS) released the first full year of data under The Affordable Care Act’s transparency program, also known as Open Payments or the "Sunshine Act." This included approximately 11.4 million records totaling about $6.5 billion in payments made to 607,000 physicians and 1,121 teaching hospitals by 1,444 reporting entities during 2014. Combined with CMS’s September 2014 release of 2013 data for the period Aug. 1, 2013 through Dec.
